Evidence map›Paper›PMID 40912407›Full record

ArticleSLAS discovery : advancing life sciences R & D2025

Integrating AUROC and SSMD for quality control in high-throughput screening assays.

Xiaohua Douglas Zhang

Abstract read
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CytokineProfile: An Integrated Web Tool for Cytokine Profiling Analysis.Computational and structural biotechnology journal · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Xiaohua Douglas ZhangDepartment of Biostatistics, College of Public Health, University of Kentucky, Lexington KY40536, USA. Electronic address: douglas.zhang@uky.edu.

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
University of Kentucky Diabetes Prevention COBRE (UK-DPC)P20GM156679 · NIGMS · UNIVERSITY OF KENTUCKY · PI SIMON J FISHER, Barbara Nikolajczyk · 2025 to 2026
$6.8M
Restoration of Impaired Awareness of Hypoglycemia U01 Consortium: University of KentuckyU01DK135111 · NIDDK · UNIVERSITY OF KENTUCKY · PI SIMON J FISHER · 2022 to 2026
$2.3M
Impacting Inflammation through Mechanistic Target of Rapamycin (imTOR)R01AG084180 · NIA · UNIVERSITY OF KENTUCKY · PI Barbara Nikolajczyk · 2024 to 2026
$1.9M
NCATS NIH HHS UL1 TR001998NIA NIH HHS R01 AG084180NIDDK NIH HHS U01 DK135111NIGMS NIH HHS P20 GM156679
6 · The paper itself

Abstract

High-throughput screening (HTS) assays are pivotal in modern biomedical research, particularly in drug discovery and functional genomics. Ensuring the quality and reliability of HTS data is critical, especially when dealing with the small sample sizes that are typical in such assays. This study explores the integration of two powerful statistical metrics-Strictly Standardized Mean Difference (SSMD) and Area Under the Receiver Operating Characteristic Curve (AUROC)-for quality control (QC) in HTS. SSMD offers a standardized, interpretable measure of effect size, while AUROC provides a threshold-independent assessment of discriminative power. By establishing the theoretical and empirical relationships between AUROC and SSMD, we demonstrate how these metrics complement each other and enhance QC practices. We provide parametric, semi-parametric, and non-parametric estimation methods, and demonstrate the utility of the integrated framework in real HTS datasets. Our findings support the joint application of SSMD and AUROC as a robust and interpretable approach to improving QC in HTS, particularly under constraints of limited sample sizes of positive and negative controls.

Indexed as

High-Throughput Screening AssaysArea Under CurveDrug DiscoveryHumansQuality ControlReproducibility of ResultsROC CurveAUROCd⁺-probabilityHigh-throughput screeningQuality controlSSMD

Identifiers

PMID40912407
PMCPMC12629507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.